Work

The efficacy of nivolumab does not increase in current smokers with metastatic non-small cell lung cancer: multicenter, retrospective, and observational study

Year: 2026
Type: article
Study design: Observational Study
Abstract: This study aims to investigate differences in survival between current and former smokers receiving second-line or later nivolumab treatment for metastatic non-small cell lung cancer. This retrospective, observational study involved 544 patients from eight centres who were treated with nivolumab for non-small cell lung cancer (NSCLC) between January 2020 and January 2025. The median age was 63 (57–68), and 477 patients (87.7%) were male. The most common pathological subtype in 294 (54%) patients was adenocarcinoma. 184 (33.8%) patients were current smokers, while 320 (58.8%) patients were former smokers.The median progression-free survival (PFS) was 6.3 (5.2–7.5) months in current smokers, 11.6 (9.9–13.3) months in former smokers, and 9.4 (5.4–13.4) months in never smokers (p <0.001). The median overall survival (OS) was 8.4 (7.2–9.7) months in current smokers, 13 (11.5–14.5) months in former smokers, and 13.3 (9–17.5) months in never smokers (p <0.001). Multivariate Cox regression analysis was performed for factors affecting overall survival. Compared to current smokers, former smokers had a hazard ratio (HR) of 0.64 (95% confidence interval (CI): 0.50–0.83, p=0.001), indicating a reduced risk of mortality. In this multicenter retrospective cohort of patients with metastatic NSCLC receiving second-line or later nivolumab treatment, current smoking was associated with shorter progression-free and overall survival compared with former smoking. These findings highlight the importance of distinguishing current from former smokers when evaluating survival outcomes in patients receiving immunotherapy. Not applicable.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,090
OpenAlex ID: W7235134566
FWCI:
Cites:
Cited by:
Related to: 10